We evaluated the effect of zoledronic acid (ZA) on serum levels of osteoprotegerin (OPG) and the ligand for receptor activator of nuclear factor kappaB (RANKL) in patients with smoldering myeloma. In treated subjects we found an increase of OPG accounting for an effect of ZA on osteoblast and/or bone marrow stromal cells together with the direct effect on osteoclasts.
Martini, G., Gozzetti, A., Gennari, L., Avanzati, A., Nuti, R., Lauria, F. (2006). The effect of zoledronic acid on serum osteoprotegerin in early stage multiple myeloma. HAEMATOLOGICA, 91(12), 1720-1721.
The effect of zoledronic acid on serum osteoprotegerin in early stage multiple myeloma
MARTINI G.;GOZZETTI A.;GENNARI L.;NUTI R.;
2006-01-01
Abstract
We evaluated the effect of zoledronic acid (ZA) on serum levels of osteoprotegerin (OPG) and the ligand for receptor activator of nuclear factor kappaB (RANKL) in patients with smoldering myeloma. In treated subjects we found an increase of OPG accounting for an effect of ZA on osteoblast and/or bone marrow stromal cells together with the direct effect on osteoclasts.
| File | Dimensione | Formato | |
|---|---|---|---|
|
martini 2006.PDF
accesso aperto
Tipologia:
PDF editoriale
Licenza:
Creative commons
Dimensione
161.09 kB
Formato
Adobe PDF
|
161.09 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
https://hdl.handle.net/11365/19322
Attenzione
Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo